In this interview discover further details of the JAVELIN Merkel 200 that led to the approval of the first immunotherapy treatment indicated in the EU and the first US FDA-approved systemic therapy for merkel cell carcinoma.
Browsing: metastatic melanoma
This article provides a immunotherapy perspective of Ipilimumab, a CTLA-4-targeted monoclonal antibody, reviewing drug mechanism, blockade, combination therapies and future prospectives.
In this editorial from Melanoma Management the authors examine melanoma clinical trials with a focus upon targeted therapies and melanoma vaccines.
Melanoma brain metastases: promising results for immune and targeted therapies combined with radiosurgery
Researchers demonstrate promising results for the use of immunological and targeted therapies in combination with stereotactic radiosurgery in melanoma brain metastases patients.
Improved survival reported for melanoma patients treated with combination ipilimumab and local therapies
A new retrospective study suggests melanoma patients who received peripheral treatments in combination with ipilimumab had significantly increased overall survival compared with patients who received ipilimumab alone.
Combining transfer of antitumor T cells with ipilimumab therapy in metastatic melanoma reported to eradicate tumors in one individual, who remains disease free over 5 years later.
Given the continued significance of immunotherapy in the treatment of metastatic melanoma, this opinion article from our partner journal Melanoma Management discusses whether elderly melanoma patients should be treated with these agents.
The end of the beginning: PD-1 inhibition as the new standard of care first-line immunotherapy in metastatic melanoma
This article reviews the clinical data from individual, comparative and combination studies, which collectively establish PD-1 inhibition as the new choice for first-line immunotherapy in metastatic melanoma.
This peer-reviewed article highlights recent innovations in melanoma immunotherapy and offers a critical perspective of the future directions of this field.
A number of local therapies have been shown to be beneficial in a subset of patients with surgically unresectable melanoma – this editorial article discusses the oncolytic intratumoral vaccine talimogene laherparepvec.